Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The proto-oncogene SRC phosphorylates cGAS to inhibit an antitumor immune response
William Dunker, Shivam A. Zaver, Jose Mario Bello Pineda, Cameron J. Howard, Robert K. Bradley, Joshua J. Woodward
William Dunker, Shivam A. Zaver, Jose Mario Bello Pineda, Cameron J. Howard, Robert K. Bradley, Joshua J. Woodward
View: Text | PDF
Research Article Immunology Oncology

The proto-oncogene SRC phosphorylates cGAS to inhibit an antitumor immune response

  • Text
  • PDF
Abstract

Cyclic GMP-AMP synthase (cGAS) is a DNA sensor and responsible for inducing an antitumor immune response. Recent studies reveal that cGAS is frequently inhibited in cancer, and therapeutic targets to promote antitumor cGAS function remain elusive. SRC is a proto-oncogene tyrosine kinase and is expressed at elevated levels in numerous cancers. Here, we demonstrate that SRC expression in primary and metastatic bladder cancer negatively correlates with innate immune gene expression and immune cell infiltration. We determine that SRC restricts cGAS signaling in human cell lines through SRC small molecule inhibitors, depletion, and overexpression. cGAS and SRC interact in cells and in vitro, while SRC directly inhibits cGAS enzymatic activity and DNA binding in a kinase-dependent manner. SRC phosphorylates cGAS, and inhibition of cGAS Y248 phosphorylation partially reduces SRC inhibition. Collectively, our study demonstrates that cGAS antitumor signaling is hindered by the proto-oncogene SRC and describes how cancer-associated proteins can regulate the innate immune system.

Authors

William Dunker, Shivam A. Zaver, Jose Mario Bello Pineda, Cameron J. Howard, Robert K. Bradley, Joshua J. Woodward

×

Figure 5

SRC kinase activity restricts cGAS DNA binding.

Options: View larger image (or click on image) Download as PowerPoint
SRC kinase activity restricts cGAS DNA binding.
(A) Schematic of FLAG-cG...
(A) Schematic of FLAG-cGAS IP qPCR. HEK293T cells were transfected with EV, FLAG-cGAS pcDNA3, and SRC-HA pcDNA3 for 24 hours. Cells were crosslinked and subjected to FLAG IP coupled with qPCR analysis to detect bound pcDNA3 vector. (B) Western blot of FLAG-cGAS IP qPCR described in A. Arrow depicts nonspecific band. (C) IP qPCR analysis from FLAG-IP in B. Samples were quantified by percent input. Three different regions of pcDNA3 (pc1, pc2, pc3) were analyzed as well as nonspecific GAPDH (n = 3). (D) IP qPCR analysis of HEK293T cells transfected with FLAG-cGAS pcDNA3 and EV, WT, or K298M SRC-HA pcDNA3 followed by FLAG-cGAS (n = 3). (E) Western blot of HEK293T cells transfected with FLAG-cGAS pcDNA3 and EV, WT, or K298M SRC-HA pcDNA3 for 24 hours. Cells were then transfected with 4 μg/mL biotinylated or unmodified ISD45 for 2 hours followed by streptavidin (strep) IP. (F) Quantification of FLAG-cGAS enrichment from E. Actin was used as a Western blot loading control. Statistical significance tests: Student’s t test (C); 1-way ANOVA with Tukey test (D). Representative assays shown. n = 3 (C–F).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts